ArticleActa neurochirurgica2026
Cerebral vasospasm following arteriovenous malformation rupture: a population-based longitudinal study.
Article in Acta neurochirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gabapentin and cognitive impairment after traumatic brain injury: A multinational cohort of 49,925 patients.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVasospasm is a devastating sequelae of ruptured arteriovenous malformations (AVMs) in adults. Comorbidities and presenting factors have been suggested as risks, but only in cross-sectional studies. The objective of this study was to characterize risk factors associated with vasospasm and mortality in ruptured AVM.
methodsAdult patients from the TriNetX Research Network were included, based on the ICD-10 codes, over a period of 20 years. Cox proportional hazard models assessed the hazards of vasospasm (I67.84) and mortality separately, adjusting for age, sex, comorbidities, substance use history, presenting factors (e.g., hypernatremia, hypokalemia), criteria of the National Inpatient Sample-Subarachnoid Hemorrhage Severity Score, and location of hemorrhage. Outcomes were assessed in the first 30 days following rupture.
resultsAmong 10,375 patients with ruptured AVMs, 523 (5.3%) died and 297 (3.0%) experienced vasospasm in the first 30 days. After matching for age and sex, vasospasm was associated with increased mortality at three months (11.1% vs. 4.8%, p = 0.003), six months (12.6% vs. 5.1%, p = 0.001), and one year (13.5% vs. 6.9%, p = 0.005). Female sex was protective against vasospasm within 30 days (HR = 0.714, p = 0.007) while the greatest risk factors present on admission included subarachnoid hemorrhage (6.086, p < 0.001), hydrocephalus (3.783, p < 0.001), and leukocytosis (2.0677, p < 0.001). The greatest risk factors for 30-day mortality were coma (HR = 3.700, p < 0.001), hydrocephalus (2.698, p < 0.001), and chronic kidney disease (1.596, p = 0.003).
conclusionsIn this retrospective cohort study of 10,375 adult patients with ruptured AVMs, vasospasm occurred in approximately 3%. Risk factors for vasospasm included subarachnoid hemorrhage, male sex, hydrocephalus, and leukocytosis. The presence of vasospasm was associated with a more than twofold increase in mortality at both 30 days and one year.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.